PRELIMINARY ANALYSIS ON EFFICACY OF RITONAVIR-BOOSTED NIRMATRELVIR ON DISEASE PROGRESSION AMONG HIGH-RISK HOSPITALISED COVID-19 PATIENTS: A RETROSPECTIVE CASE-CONTROL STUDY

被引：0
|
作者：
Lee, S. P. [1 ]
Chuah, C. H. [1 ]
Mak, W. Y. [2 ]
Tan, J. W. [1 ]
Lee, J. N. [1 ]
Bidin, F. N. [1 ]
Leong, K. N. [1 ]
Wong, P. S. [1 ]
Chow, T. S. [1 ]
机构：
[1] Hosp Pulau Pinang, Infect Dis Unit, Georgetown, Malaysia
[2] Hosp Pulau Pinang, Clin Res Ctr, Georgetown, Malaysia
来源：
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2023年 / 130卷
关键词：
D O I：
10.1016/j.ijid.2023.04.287
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S116 / S116
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS AT HIGH-RISK FOR PROGRESSION IN SPAIN
    Peral, C.
    Azanza, J. R.
    Gonzalez del Castillo, J. M.
    Ferrando, R.
    Molero Garcia, J. M.
    Soriano, A.
    Ariznavarreta Martin, A.
    Gari, C.
    De Lossada Juste, A.
    Lopez Gomez, V
    VALUE IN HEALTH, 2024, 27 (12) : S129 - S129
  • [2] Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain
    Azanza, Jose Ramon
    Gonzalez Del Castillo, Juan Maria
    Ferrando, Raul
    Molero, Jose Maria
    Soriano, Alex
    Peral, Carmen
    de Lossada, Alfonso
    Bellmunt, Alba
    Gari, Carla
    Mugwagwa, Tendai
    Lopez-Gomez, Vanessa
    JOURNAL OF MEDICAL VIROLOGY, 2025, 97 (03)
  • [3] Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: A retrospective observational study
    Kane, Anna M.
    Keenan, Erica M.
    Lee, Kasheng
    Hartkopf, Katherine J.
    Ludwig, Trisha A.
    Trapskin, Philip J.
    Vanderloo, Joshua P.
    Schulz, Lucas T.
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2023, 6 (01): : 29 - 33
  • [4] Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease
    Hoertel, Nicolas
    Boulware, David R.
    Sanchez-Rico, Marina
    Burgun, Anita
    Limosin, Frederic
    JAMA NETWORK OPEN, 2022, 5 (11) : e2242140
  • [5] Nirmatrelvir-ritonavir efficacy and safety in high-risk COVID-19 patients: a review of recent retrospective cohort studies - nephrology point of view
    Amin, Alireza
    Maleki, Shiva
    Moonesan, Mohammad Reza
    JOURNAL OF RENAL INJURY PREVENTION, 2024,
  • [6] Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression
    Butt, Adeel Ajwad
    Yan, Peng
    Shaikh, Obaid S.
    PLOS ONE, 2024, 19 (06):
  • [7] BUDGET IMPACT OF ORAL NIRMATRELVIR/RITONAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN THE US
    Sandin, R.
    Veenstra, D.
    Dzingina, M.
    Vankelegom, M.
    Sullivan, S.
    Campbell, D.
    Ma, C.
    Harrison, C.
    Draica, F.
    Wiemken, T. L.
    Mugwagwa, T.
    VALUE IN HEALTH, 2023, 26 (12) : S177 - S177
  • [8] BUDGET IMPACT OF ORAL NIRMATRELVIR/RITONAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN THE US: AN UPDATED ANALYSIS
    Campbell, D.
    Veenstra, D.
    Migliaccio-Walle, K.
    Dzingina, M.
    Sullivan, S.
    Draica, F.
    Wiemken, T.
    Cha-Silva, A.
    Mugwagwa, T.
    VALUE IN HEALTH, 2024, 27 (06) : S119 - S119
  • [9] Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study
    Chen, Xiaohua
    Zhu, Ying
    Shen, Leer
    Zhou, Dan
    Feng, Nannan
    Tong, Qiang
    JOURNAL OF INTENSIVE CARE MEDICINE, 2024, 39 (08) : 742 - 750
  • [10] US Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients
    Cullen, Mark R.
    Zhou, Xiaofeng
    Kelly, Scott P.
    Liang, Caihua
    Li, Ling
    Shen, Rongjun
    Leister-Tebbe, Heidi K.
    Terra, Steven G.
    Gaffney, Michael
    Russo, Leo
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2024, 101
12345